25 XP   0   0   10

Vicore Pharma Holding AB (publ)
Buy, Hold or Sell?

Let's analyse Vicore Pharma Holding AB (publ) together

PenkeI guess you are interested in Vicore Pharma Holding AB (publ). Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Vicore Pharma Holding AB (publ). At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Vicore Pharma Holding AB (publ)

I send you an email if I find something interesting about Vicore Pharma Holding AB (publ).

Quick analysis of Vicore Pharma Holding AB (publ) (30 sec.)










What can you expect buying and holding a share of Vicore Pharma Holding AB (publ)? (30 sec.)

How much money do you get?

How much money do you get?
kr0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
kr4.08
Expected worth in 1 year
kr5.56
How sure are you?
40.6%

+ What do you gain per year?

Total Gains per Share
kr1.49
Return On Investment
9.1%

For what price can you sell your share?

Current Price per Share
kr16.32
Expected price per share
kr12.84 - kr19.02
How sure are you?
50%

1. Valuation of Vicore Pharma Holding AB (publ) (5 min.)




Live pricePrice per Share (EOD)

kr16.32

Intrinsic Value Per Share

kr-29.07 - kr-33.96

Total Value Per Share

kr-25.00 - kr-29.88

2. Growth of Vicore Pharma Holding AB (publ) (5 min.)




Is Vicore Pharma Holding AB (publ) growing?

Current yearPrevious yearGrowGrow %
How rich?$41.5m$22m$13.2m37.4%

How much money is Vicore Pharma Holding AB (publ) making?

Current yearPrevious yearGrowGrow %
Making money-$7m-$6.5m-$513.4k-7.2%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Vicore Pharma Holding AB (publ) (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#498 / 1016

Most Revenue
#795 / 1016

Most Profit
#485 / 1016

Most Efficient
#241 / 1016

What can you expect buying and holding a share of Vicore Pharma Holding AB (publ)? (5 min.)

Welcome investor! Vicore Pharma Holding AB (publ)'s management wants to use your money to grow the business. In return you get a share of Vicore Pharma Holding AB (publ).

What can you expect buying and holding a share of Vicore Pharma Holding AB (publ)?

First you should know what it really means to hold a share of Vicore Pharma Holding AB (publ). And how you can make/lose money.

Speculation

The Price per Share of Vicore Pharma Holding AB (publ) is kr16.32. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Vicore Pharma Holding AB (publ).
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Vicore Pharma Holding AB (publ), you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is kr4.08. Based on the TTM, the Book Value Change Per Share is kr0.37 per quarter. Based on the YOY, the Book Value Change Per Share is kr-0.21 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is kr0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Vicore Pharma Holding AB (publ).

How much money are you going to get?

 MRQTTMYOY5Y10Y
 kr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Share
Usd Eps-0.09-0.6%-0.06-0.4%-0.06-0.4%-0.05-0.3%-0.03-0.2%
Usd Book Value Change Per Share-0.09-0.6%0.030.2%-0.02-0.1%0.010.0%0.010.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.09-0.6%0.030.2%-0.02-0.1%0.010.0%0.010.1%
Usd Price Per Share1.29-1.48-2.19-1.78-1.60-
Price to Earnings Ratio-3.54--6.23--9.50--12.17--54.63-
Price-to-Total Gains Ratio-14.26--3.73--26.65--41.13--118.35-
Price to Book Ratio3.48-5.49-12.17-7.17-9.76-
Price-to-Total Gains Ratio-14.26--3.73--26.65--41.13--118.35-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.488384
Number of shares671
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.030.01
Usd Total Gains Per Share0.030.01
Gains per Quarter (671 shares)22.774.65
Gains per Year (671 shares)91.0918.62
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1091810199
2018217203728
3027326305647
4036435407466
5045544509385
605475360112104
706386270130123
807297180149142
908208090168161
1009119000186180

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%2.030.00.06.3%2.030.00.06.3%
Book Value Change Per Share2.02.00.050.0%4.08.00.033.3%6.014.00.030.0%13.019.00.040.6%13.019.00.040.6%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.032.00.0%0.00.032.00.0%
Total Gains per Share2.02.00.050.0%4.08.00.033.3%6.014.00.030.0%13.019.00.040.6%13.019.00.040.6%

Fundamentals of Vicore Pharma Holding AB (publ)

About Vicore Pharma Holding AB (publ)

Vicore Pharma Holding AB (publ) engages in the research and development of pharmaceutical products for the treatments for rare lung diseases. The company's portfolio includes idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH) diseases. The company develops C21, a low molecular weight angiotensin II type 2 receptor agonist ATRAG; Almee, an investigational medical device in clinical development to address the psychological impact of living with pulmonary fibrosis; Inhaled IMID for the severe cough associated with IPF; and C103, C111, and C112. It has a collaboration and development agreement with Emeriti Bio AB. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is based in Stockholm, Sweden.

Fundamental data was last updated by Penke on 2024-04-03 08:30:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Vicore Pharma Holding AB (publ).

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Vicore Pharma Holding AB (publ) earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compare Vicore Pharma Holding AB (publ) to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that kr0.00 for each kr1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Vicore Pharma Holding AB (publ):

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-2,422.7%+2,422.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--199.6%+199.6%
TTM--213.0%+213.0%
YOY--279.3%+279.3%
5Y--438.4%+438.4%
10Y-2,422.7%-605.5%-1,817.2%
1.1.2. Return on Assets

Shows how efficient Vicore Pharma Holding AB (publ) is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Vicore Pharma Holding AB (publ) to the Biotechnology industry mean.
  • -22.5% Return on Assets means that Vicore Pharma Holding AB (publ) generated kr-0.23 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Vicore Pharma Holding AB (publ):

  • The MRQ is -22.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -19.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-22.5%TTM-19.6%-3.0%
TTM-19.6%YOY-22.6%+3.1%
TTM-19.6%5Y-14.8%-4.8%
5Y-14.8%10Y-10.0%-4.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-22.5%-13.5%-9.0%
TTM-19.6%-12.9%-6.7%
YOY-22.6%-11.8%-10.8%
5Y-14.8%-14.1%-0.7%
10Y-10.0%-16.0%+6.0%
1.1.3. Return on Equity

Shows how efficient Vicore Pharma Holding AB (publ) is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Vicore Pharma Holding AB (publ) to the Biotechnology industry mean.
  • -24.6% Return on Equity means Vicore Pharma Holding AB (publ) generated kr-0.25 for each kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Vicore Pharma Holding AB (publ):

  • The MRQ is -24.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -22.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-24.6%TTM-22.1%-2.5%
TTM-22.1%YOY-31.1%+9.1%
TTM-22.1%5Y-17.7%-4.4%
5Y-17.7%10Y-11.8%-5.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-24.6%-16.9%-7.7%
TTM-22.1%-16.1%-6.0%
YOY-31.1%-15.1%-16.0%
5Y-17.7%-19.9%+2.2%
10Y-11.8%-20.9%+9.1%

1.2. Operating Efficiency of Vicore Pharma Holding AB (publ).

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Vicore Pharma Holding AB (publ) is operating .

  • Measures how much profit Vicore Pharma Holding AB (publ) makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Vicore Pharma Holding AB (publ) to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated kr0.00  for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Vicore Pharma Holding AB (publ):

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-2,410.3%+2,410.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--295.1%+295.1%
TTM--225.8%+225.8%
YOY--288.4%+288.4%
5Y--477.4%+477.4%
10Y-2,410.3%-625.6%-1,784.7%
1.2.2. Operating Ratio

Measures how efficient Vicore Pharma Holding AB (publ) is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are kr0.00 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of Vicore Pharma Holding AB (publ):

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y28.729-28.729
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.090-3.090
TTM-3.264-3.264
YOY-3.783-3.783
5Y-5.679-5.679
10Y28.7297.894+20.835

1.3. Liquidity of Vicore Pharma Holding AB (publ).

1.3. Liquidity
1.3.1. Current Ratio

Measures if Vicore Pharma Holding AB (publ) is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 12.55 means the company has kr12.55 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of Vicore Pharma Holding AB (publ):

  • The MRQ is 12.548. The company is very able to pay all its short-term debts. +2
  • The TTM is 9.570. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ12.548TTM9.570+2.979
TTM9.570YOY3.604+5.966
TTM9.5705Y10.244-0.675
5Y10.24410Y9.456+0.788
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ12.5483.914+8.634
TTM9.5704.220+5.350
YOY3.6045.388-1.784
5Y10.2446.045+4.199
10Y9.4566.406+3.050
1.3.2. Quick Ratio

Measures if Vicore Pharma Holding AB (publ) is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Vicore Pharma Holding AB (publ) to the Biotechnology industry mean.
  • A Quick Ratio of 16.09 means the company can pay off kr16.09 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Vicore Pharma Holding AB (publ):

  • The MRQ is 16.091. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 11.420. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ16.091TTM11.420+4.670
TTM11.420YOY3.564+7.857
TTM11.4205Y12.045-0.624
5Y12.04510Y10.497+1.548
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ16.0913.572+12.519
TTM11.4203.998+7.422
YOY3.5645.390-1.826
5Y12.0455.969+6.076
10Y10.4976.287+4.210

1.4. Solvency of Vicore Pharma Holding AB (publ).

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Vicore Pharma Holding AB (publ) assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Vicore Pharma Holding AB (publ) to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.08 means that Vicore Pharma Holding AB (publ) assets are financed with 8.2% credit (debt) and the remaining percentage (100% - 8.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Vicore Pharma Holding AB (publ):

  • The MRQ is 0.082. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.105. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.082TTM0.105-0.023
TTM0.105YOY0.256-0.150
TTM0.1055Y0.121-0.016
5Y0.12110Y0.101+0.020
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0820.336-0.254
TTM0.1050.334-0.229
YOY0.2560.269-0.013
5Y0.1210.366-0.245
10Y0.1010.390-0.289
1.4.2. Debt to Equity Ratio

Measures if Vicore Pharma Holding AB (publ) is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Vicore Pharma Holding AB (publ) to the Biotechnology industry mean.
  • A Debt to Equity ratio of 9.0% means that company has kr0.09 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Vicore Pharma Holding AB (publ):

  • The MRQ is 0.090. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.119. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.090TTM0.119-0.029
TTM0.119YOY0.358-0.240
TTM0.1195Y0.149-0.031
5Y0.14910Y0.121+0.028
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0900.382-0.292
TTM0.1190.396-0.277
YOY0.3580.335+0.023
5Y0.1490.434-0.285
10Y0.1210.465-0.344

2. Market Valuation of Vicore Pharma Holding AB (publ)

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every kr1 in earnings Vicore Pharma Holding AB (publ) generates.

  • Above 15 is considered overpriced but always compare Vicore Pharma Holding AB (publ) to the Biotechnology industry mean.
  • A PE ratio of -3.54 means the investor is paying kr-3.54 for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Vicore Pharma Holding AB (publ):

  • The EOD is -4.074. Based on the earnings, the company is expensive. -2
  • The MRQ is -3.540. Based on the earnings, the company is expensive. -2
  • The TTM is -6.227. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.074MRQ-3.540-0.534
MRQ-3.540TTM-6.227+2.688
TTM-6.227YOY-9.504+3.276
TTM-6.2275Y-12.175+5.947
5Y-12.17510Y-54.635+42.460
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.074-2.259-1.815
MRQ-3.540-2.569-0.971
TTM-6.227-2.664-3.563
YOY-9.504-4.120-5.384
5Y-12.175-6.258-5.917
10Y-54.635-6.171-48.464
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Vicore Pharma Holding AB (publ):

  • The EOD is -6.757. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -5.871. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -7.870. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.757MRQ-5.871-0.886
MRQ-5.871TTM-7.870+1.999
TTM-7.870YOY-9.351+1.482
TTM-7.8705Y-13.311+5.441
5Y-13.31110Y-28.709+15.399
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.757-2.924-3.833
MRQ-5.871-3.246-2.625
TTM-7.870-3.488-4.382
YOY-9.351-5.620-3.731
5Y-13.311-8.315-4.996
10Y-28.709-8.826-19.883
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Vicore Pharma Holding AB (publ) is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.48 means the investor is paying kr3.48 for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of Vicore Pharma Holding AB (publ):

  • The EOD is 4.004. Based on the equity, the company is fair priced.
  • The MRQ is 3.479. Based on the equity, the company is fair priced.
  • The TTM is 5.490. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD4.004MRQ3.479+0.525
MRQ3.479TTM5.490-2.011
TTM5.490YOY12.167-6.676
TTM5.4905Y7.174-1.684
5Y7.17410Y9.756-2.582
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.0041.851+2.153
MRQ3.4792.090+1.389
TTM5.4902.095+3.395
YOY12.1672.844+9.323
5Y7.1743.466+3.708
10Y9.7563.815+5.941
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Vicore Pharma Holding AB (publ) compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.9940.372-367%-0.211-79%0.076-1407%0.127-881%
Book Value Per Share--4.0763.465+18%2.168+88%3.121+31%2.353+73%
Current Ratio--12.5489.570+31%3.604+248%10.244+22%9.456+33%
Debt To Asset Ratio--0.0820.105-22%0.256-68%0.121-32%0.101-18%
Debt To Equity Ratio--0.0900.119-24%0.358-75%0.149-40%0.121-26%
Dividend Per Share----0%-0%-0%-0%
Eps---1.002-0.696-31%-0.645-36%-0.508-49%-0.329-67%
Free Cash Flow Per Share---0.604-0.558-8%-0.678+12%-0.460-24%-0.311-49%
Free Cash Flow To Equity Per Share---0.6040.495-222%-0.259-57%0.113-635%0.123-593%
Gross Profit Margin--1.0171.026-1%1.031-1%1.012+0%1.010+1%
Intrinsic Value_10Y_max---33.960--------
Intrinsic Value_10Y_min---29.075--------
Intrinsic Value_1Y_max---2.583--------
Intrinsic Value_1Y_min---2.536--------
Intrinsic Value_3Y_max---8.385--------
Intrinsic Value_3Y_min---7.992--------
Intrinsic Value_5Y_max---14.941--------
Intrinsic Value_5Y_min---13.814--------
Market Cap1823319360.000+13%1584232140.0001814381520.000-13%2678558925.000-41%2182676389.500-27%1957840136.419-19%
Net Profit Margin----0%-0%-0%-24.2270%
Operating Margin----0%-0%-0%-24.1030%
Operating Ratio----0%-0%-0%28.729-100%
Pb Ratio4.004+13%3.4795.490-37%12.167-71%7.174-52%9.756-64%
Pe Ratio-4.074-15%-3.540-6.227+76%-9.504+168%-12.175+244%-54.635+1443%
Price Per Share16.320+13%14.18016.240-13%23.975-41%19.537-27%17.524-19%
Price To Free Cash Flow Ratio-6.757-15%-5.871-7.870+34%-9.351+59%-13.311+127%-28.709+389%
Price To Total Gains Ratio-16.411-15%-14.259-3.732-74%-26.654+87%-41.131+188%-118.353+730%
Quick Ratio--16.09111.420+41%3.564+352%12.045+34%10.497+53%
Return On Assets---0.225-0.196-13%-0.226+0%-0.148-34%-0.100-56%
Return On Equity---0.246-0.221-10%-0.311+27%-0.177-28%-0.118-52%
Total Gains Per Share---0.9940.372-367%-0.211-79%0.076-1407%0.127-881%
Usd Book Value--41531476.80035307783.600+18%22094978.400+88%31800268.080+31%23972415.900+73%
Usd Book Value Change Per Share---0.0910.034-367%-0.019-79%0.007-1407%0.012-881%
Usd Book Value Per Share--0.3720.316+18%0.198+88%0.285+31%0.215+73%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.091-0.063-31%-0.059-36%-0.046-49%-0.030-67%
Usd Free Cash Flow---6152808.000-5690492.400-8%-6906553.200+12%-4686558.240-24%-3166609.350-49%
Usd Free Cash Flow Per Share---0.055-0.051-8%-0.062+12%-0.042-24%-0.028-49%
Usd Free Cash Flow To Equity Per Share---0.0550.045-222%-0.024-57%0.010-635%0.011-593%
Usd Market Cap166286725.632+13%144481971.168165471594.624-13%244284573.960-41%199060086.722-27%178555020.441-19%
Usd Price Per Share1.488+13%1.2931.481-13%2.187-41%1.782-27%1.598-19%
Usd Profit---10204459.200-7089477.600-31%-6576021.600-36%-5179206.960-49%-3354187.800-67%
Usd Revenue----0%-0%-0%6532.200-100%
Usd Total Gains Per Share---0.0910.034-367%-0.019-79%0.007-1407%0.012-881%
 EOD+5 -3MRQTTM+9 -21YOY+15 -155Y+11 -1910Y+12 -20

3.2. Fundamental Score

Let's check the fundamental score of Vicore Pharma Holding AB (publ) based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.074
Price to Book Ratio (EOD)Between0-14.004
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than116.091
Current Ratio (MRQ)Greater than112.548
Debt to Asset Ratio (MRQ)Less than10.082
Debt to Equity Ratio (MRQ)Less than10.090
Return on Equity (MRQ)Greater than0.15-0.246
Return on Assets (MRQ)Greater than0.05-0.225
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Vicore Pharma Holding AB (publ) based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5051.146
Ma 20Greater thanMa 5016.359
Ma 50Greater thanMa 10015.387
Ma 100Greater thanMa 20014.834
OpenGreater thanClose16.060
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in SEK. All numbers in thousands.

Summary
Total Assets496,248
Total Liabilities40,859
Total Stockholder Equity455,389
 As reported
Total Liabilities 40,859
Total Stockholder Equity+ 455,389
Total Assets = 496,248

Assets

Total Assets496,248
Total Current Assets494,005
Long-term Assets2,243
Total Current Assets
Cash And Cash Equivalents 333,620
Short-term Investments 149,146
Net Receivables 1,540
Other Current Assets 9,699
Total Current Assets  (as reported)494,005
Total Current Assets  (calculated)494,005
+/-0
Long-term Assets
Property Plant Equipment 25
Intangible Assets 2,218
Long-term Assets Other 0
Long-term Assets  (as reported)2,243
Long-term Assets  (calculated)2,243
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities39,368
Long-term Liabilities1,491
Total Stockholder Equity455,389
Total Current Liabilities
Accounts payable 16,326
Other Current Liabilities 23,042
Total Current Liabilities  (as reported)39,368
Total Current Liabilities  (calculated)39,368
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)1,491
Long-term Liabilities  (calculated)0
+/- 1,491
Total Stockholder Equity
Common Stock55,861
Retained Earnings -1,274,262
Other Stockholders Equity 1,673,790
Total Stockholder Equity (as reported)455,389
Total Stockholder Equity (calculated)455,389
+/-0
Other
Capital Stock55,861
Cash and Short Term Investments 482,766
Common Stock Shares Outstanding 111,723
Liabilities and Stockholders Equity 496,248
Net Debt -333,620
Net Invested Capital 455,389
Net Working Capital 454,637
Property Plant and Equipment Gross 147



Balance Sheet

Currency in SEK. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-31
> Total Assets 
59,368
0
65,258
0
89,225
84,896
82,334
81,927
81,650
107,970
124,931
123,430
119,527
124,138
143,654
172,112
301,600
293,140
268,759
248,465
341,108
313,866
291,168
440,047
406,515
673,620
617,908
528,996
451,168
377,741
321,492
250,182
338,007
264,543
340,076
612,556
496,248
496,248612,556340,076264,543338,007250,182321,492377,741451,168528,996617,908673,620406,515440,047291,168313,866341,108248,465268,759293,140301,600172,112143,654124,138119,527123,430124,931107,97081,65081,92782,33484,89689,225065,258059,368
   > Total Current Assets 
2,095
0
5,436
0
26,346
18,914
13,466
9,968
4,799
28,128
40,812
33,542
24,725
14,670
19,424
33,264
226,820
218,172
195,259
175,704
266,515
240,017
215,214
366,703
327,847
596,670
542,286
455,463
377,931
308,908
248,990
177,664
269,790
197,228
273,601
558,919
494,005
494,005558,919273,601197,228269,790177,664248,990308,908377,931455,463542,286596,670327,847366,703215,214240,017266,515175,704195,259218,172226,82033,26419,42414,67024,72533,54240,81228,1284,7999,96813,46618,91426,34605,43602,095
       Cash And Cash Equivalents 
1,710
0
5,000
0
25,175
18,422
13,038
8,918
4,266
27,025
40,224
32,734
24,019
13,744
18,102
32,209
224,688
215,971
193,491
172,197
187,586
160,813
134,975
213,780
248,618
442,663
366,980
369,645
294,199
300,616
236,561
169,754
256,803
183,626
259,590
351,085
333,620
333,620351,085259,590183,626256,803169,754236,561300,616294,199369,645366,980442,663248,618213,780134,975160,813187,586172,197193,491215,971224,68832,20918,10213,74424,01932,73440,22427,0254,2668,91813,03818,42225,17505,00001,710
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
77,000
77,211
77,392
147,600
70,000
147,258
147,456
77,270
77,000
8
0
0
4,940
0
0
200,426
149,146
149,146200,426004,94000877,00077,270147,456147,25870,000147,60077,39277,21177,00000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,426
1,586
1,029
1,454
8,505
2,385
2,400
1,552
1,417
3,685
8,922
4,012
2,180
4,439
1,601
2,564
1,540
1,5402,5641,6014,4392,1804,0128,9223,6851,4171,5522,4002,3858,5051,4541,0291,5861,42600000000000000000000
       Other Current Assets 
385
0
436
0
1,171
492
428
1,050
533
1,103
588
808
706
926
1,322
1,055
2,132
2,201
1,768
3,507
1,929
1,993
2,847
5,323
9,229
6,749
27,850
8,548
6,732
8,284
12,429
7,910
5,867
9,163
12,410
4,844
9,699
9,6994,84412,4109,1635,8677,91012,4298,2846,7328,54827,8506,7499,2295,3232,8471,9931,9293,5071,7682,2012,1321,0551,3229267068085881,1035331,0504284921,17104360385
   > Long-term Assets 
57,273
0
59,822
0
62,879
65,982
68,868
71,959
76,851
79,842
84,119
89,888
94,802
109,468
124,230
138,848
74,780
74,968
73,500
72,761
74,593
73,849
75,954
73,344
78,668
76,950
75,622
73,533
73,237
68,833
72,502
72,518
68,217
67,315
66,475
53,637
2,243
2,24353,63766,47567,31568,21772,51872,50268,83373,23773,53375,62276,95078,66873,34475,95473,84974,59372,76173,50074,96874,780138,848124,230109,46894,80289,88884,11979,84276,85171,95968,86865,98262,879059,822057,273
       Property Plant Equipment 
58
0
13
0
8
6
5
3
2
34
32
30
28
27
25
23
21
20
0
0
143
135
128
120
113
105
98
91
84
76
69
61
54
47
39
32
25
25323947546169768491981051131201281351430020212325272830323423568013058
       Intangible Assets 
0
0
0
0
42,761
45,866
48,753
51,346
56,239
59,198
63,477
69,248
72,029
76,450
81,659
136,942
69,192
69,192
69,192
68,914
68,082
67,250
66,418
65,586
70,755
69,923
69,091
68,259
67,427
64,596
69,764
68,932
68,100
67,268
66,436
53,605
2,218
2,21853,60566,43667,26868,10068,93269,76464,59667,42768,25969,09169,92370,75565,58666,41867,25068,08268,91469,19269,19269,192136,94281,65976,45072,02969,24863,47759,19856,23951,34648,75345,86642,7610000
       Long-term Assets Other 
20,110
0
20,110
0
20,110
20,110
20,110
20,610
20,610
20,610
20,610
20,610
22,745
32,991
42,546
1,883
5,567
5,756
4,308
3,847
77,189
77,365
77,515
147,809
70,139
147,328
147,900
77,650
77,317
262
2,669
3,525
63
0
0
0
0
0000633,5252,66926277,31777,650147,900147,32870,139147,80977,51577,36577,1893,8474,3085,7565,5671,88342,54632,99122,74520,61020,61020,61020,61020,61020,11020,11020,110020,110020,110
> Total Liabilities 
5,672
0
3,745
0
7,295
4,568
3,348
4,529
6,053
6,042
3,687
3,873
6,559
6,912
21,314
27,489
16,164
13,392
15,046
17,205
19,511
17,604
18,436
28,054
52,002
44,471
58,711
66,398
67,852
86,523
93,414
89,483
48,924
39,946
37,965
46,066
40,859
40,85946,06637,96539,94648,92489,48393,41486,52367,85266,39858,71144,47152,00228,05418,43617,60419,51117,20515,04613,39216,16427,48921,3146,9126,5593,8733,6876,0426,0534,5293,3484,5687,29503,74505,672
   > Total Current Liabilities 
3,694
0
1,767
0
5,317
2,590
1,370
2,551
4,075
4,064
1,709
1,895
4,581
4,934
19,336
25,511
13,908
11,003
11,880
14,480
16,954
15,487
15,535
25,451
48,086
40,642
55,173
62,956
65,722
83,427
89,252
84,168
46,419
37,294
35,489
43,896
39,368
39,36843,89635,48937,29446,41984,16889,25283,42765,72262,95655,17340,64248,08625,45115,53515,48716,95414,48011,88011,00313,90825,51119,3364,9344,5811,8951,7094,0644,0752,5511,3702,5905,31701,76703,694
       Short-term Debt 
1,500
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
65
0
0
0
0
00006500000000000000000000000000000001,500
       Accounts payable 
562
0
560
0
2,312
1,020
213
1,240
2,184
2,572
519
715
2,780
3,056
2,185
5,488
2,384
3,083
6,176
7,358
5,300
9,684
9,896
6,322
10,943
26,335
34,257
21,437
23,984
22,040
28,963
33,641
23,495
14,764
15,974
20,953
16,326
16,32620,95315,97414,76423,49533,64128,96322,04023,98421,43734,25726,33510,9436,3229,8969,6845,3007,3586,1763,0832,3845,4882,1853,0562,7807155192,5722,1841,2402131,0202,31205600562
       Other Current Liabilities 
1,632
0
1,207
0
3,005
1,570
1,157
1,311
1,891
1,492
1,190
1,180
1,801
1,878
17,151
20,023
11,524
7,920
5,704
7,122
11,654
5,803
5,639
19,129
37,143
14,307
20,916
41,263
41,403
61,387
60,289
50,527
22,924
22,530
19,515
22,943
23,042
23,04222,94319,51522,53022,92450,52760,28961,38741,40341,26320,91614,30737,14319,1295,6395,80311,6547,1225,7047,92011,52420,02317,1511,8781,8011,1801,1901,4921,8911,3111,1571,5703,00501,20701,632
   > Long-term Liabilities 
1,978
0
1,978
0
1,978
1,978
1,978
1,978
1,978
1,978
1,978
1,978
1,978
1,978
1,978
1,978
2,256
2,389
3,166
2,725
2,557
2,117
2,901
2,603
3,916
3,829
3,538
3,442
2,130
3,096
4,162
5,315
2,505
2,652
2,476
2,170
1,491
1,4912,1702,4762,6522,5055,3154,1623,0962,1303,4423,5383,8293,9162,6032,9012,1172,5572,7253,1662,3892,2561,9781,9781,9781,9781,9781,9781,9781,9781,9781,9781,9781,97801,97801,978
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
445
382
320
0
0
0
0
0
0
0
0
0000000032038244500000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,371
1,962
2,776
2,603
3,916
3,829
3,093
3,060
1,810
3,096
4,162
5,315
2,505
0
2,476
0
0
002,47602,5055,3154,1623,0961,8103,0603,0933,8293,9162,6032,7761,9622,37100000000000000000000
> Total Stockholder Equity
53,696
0
61,513
0
81,930
80,328
78,986
77,398
75,597
101,928
121,244
119,557
112,968
117,226
122,340
144,623
285,436
279,748
253,713
231,260
321,597
296,262
272,732
411,993
354,513
629,149
559,197
462,598
383,316
291,218
228,078
160,699
289,083
224,597
302,111
566,490
455,389
455,389566,490302,111224,597289,083160,699228,078291,218383,316462,598559,197629,149354,513411,993272,732296,262321,597231,260253,713279,748285,436144,623122,340117,226112,968119,557121,244101,92875,59777,39878,98680,32881,930061,513053,696
   Common Stock
3,428
0
4,060
0
6,184
6,184
6,184
6,184
6,184
19,581
20,331
20,331
7,934
39,448
39,448
43,874
20,892
0
0
0
25,087
25,209
25,209
30,209
30,209
35,880
35,880
35,880
35,880
35,880
35,924
35,924
40,924
40,924
45,524
55,861
55,861
55,86155,86145,52440,92440,92435,92435,92435,88035,88035,88035,88035,88030,20930,20925,20925,20925,08700020,89243,87439,44839,4487,93420,33120,33119,5816,1846,1846,1846,1846,18404,06003,428
   Retained Earnings Total Equity0000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 0000000000000000000000000000000000000
   Capital Surplus 0000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000
   Other Stockholders Equity 
50,268
0
57,453
0
76,306
74,144
72,802
71,214
76,625
82,347
100,913
99,226
105,034
77,778
82,892
100,749
402,347
0
0
0
527,397
271,053
247,523
381,784
702,053
593,269
523,317
462,598
1,021,666
291,218
228,078
160,699
1,210,811
183,673
256,587
510,629
1,673,790
1,673,790510,629256,587183,6731,210,811160,699228,078291,2181,021,666462,598523,317593,269702,053381,784247,523271,053527,397000402,347100,74982,89277,778105,03499,226100,91382,34776,62571,21472,80274,14476,306057,453050,268



Balance Sheet

Currency in SEK. All numbers in thousands.




Cash Flow

Currency in SEK. All numbers in thousands.




Income Statement

Currency in SEK. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-65,976
Gross Profit-65,976-65,976
 
Operating Income (+$)
Gross Profit-65,976
Operating Expense-254,913
Operating Income-320,889-320,889
 
Operating Expense (+$)
Research Development210,318
Selling General Administrative44,595
Selling And Marketing Expenses0
Operating Expense254,913254,913
 
Net Interest Income (+$)
Interest Income10,538
Interest Expense-358
Other Finance Cost-356
Net Interest Income10,536
 
Pretax Income (+$)
Operating Income-320,889
Net Interest Income10,536
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-311,326-330,452
EBIT - interestExpense = -321,247
-311,326
-310,584
Interest Expense358
Earnings Before Interest and Taxes (EBIT)-320,889-310,968
Earnings Before Interest and Taxes (EBITDA)-254,913
 
After tax Income (+$)
Income Before Tax-311,326
Tax Provision--384
Net Income From Continuing Ops-310,942-310,942
Net Income-310,942
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses320,889
Total Other Income/Expenses Net9,563-10,536
 

Technical Analysis of Vicore Pharma Holding AB (publ)
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Vicore Pharma Holding AB (publ). The general trend of Vicore Pharma Holding AB (publ) is BULLISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Vicore Pharma Holding AB (publ)'s overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (71.4%) Bearish trend (-71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Vicore Pharma Holding AB (publ).

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 18.28 < 18.66 < 19.02.

The bearish price targets are: 14.18 > 13.36 > 12.84.

Tweet this
Vicore Pharma Holding AB (publ) Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Vicore Pharma Holding AB (publ). The current mas is .

The long score for the Moving Averages is 12/14.
The longshort score for the Moving Averages is 10/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Vicore Pharma Holding AB (publ) Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Vicore Pharma Holding AB (publ). The current macd is 0.38397643.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Vicore Pharma Holding AB (publ) price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Vicore Pharma Holding AB (publ). This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Vicore Pharma Holding AB (publ) price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Vicore Pharma Holding AB (publ) Daily Moving Average Convergence/Divergence (MACD) ChartVicore Pharma Holding AB (publ) Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Vicore Pharma Holding AB (publ). The current adx is 31.07.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Vicore Pharma Holding AB (publ) shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Vicore Pharma Holding AB (publ) Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Vicore Pharma Holding AB (publ). The current sar is 18.67.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Vicore Pharma Holding AB (publ) Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Vicore Pharma Holding AB (publ). The current rsi is 51.15. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Vicore Pharma Holding AB (publ) Daily Relative Strength Index (RSI) ChartVicore Pharma Holding AB (publ) Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Vicore Pharma Holding AB (publ). The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Vicore Pharma Holding AB (publ) price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Vicore Pharma Holding AB (publ) Daily Stochastic Oscillator ChartVicore Pharma Holding AB (publ) Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Vicore Pharma Holding AB (publ). The current cci is -12.56878251.

Vicore Pharma Holding AB (publ) Daily Commodity Channel Index (CCI) ChartVicore Pharma Holding AB (publ) Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Vicore Pharma Holding AB (publ). The current cmo is -6.28426857.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Vicore Pharma Holding AB (publ) Daily Chande Momentum Oscillator (CMO) ChartVicore Pharma Holding AB (publ) Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Vicore Pharma Holding AB (publ). The current willr is -55.96707819.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Vicore Pharma Holding AB (publ) is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Vicore Pharma Holding AB (publ) Daily Williams %R ChartVicore Pharma Holding AB (publ) Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Vicore Pharma Holding AB (publ).

Vicore Pharma Holding AB (publ) Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Vicore Pharma Holding AB (publ). The current atr is 0.94484597.

Vicore Pharma Holding AB (publ) Daily Average True Range (ATR) ChartVicore Pharma Holding AB (publ) Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Vicore Pharma Holding AB (publ). The current obv is 545,196.

Vicore Pharma Holding AB (publ) Daily On-Balance Volume (OBV) ChartVicore Pharma Holding AB (publ) Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Vicore Pharma Holding AB (publ). The current mfi is 75.97.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Vicore Pharma Holding AB (publ) Daily Money Flow Index (MFI) ChartVicore Pharma Holding AB (publ) Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Vicore Pharma Holding AB (publ).

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-30STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-12CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-14STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-21CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-23CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-31DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-01STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-12WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-18BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-26WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-10MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-04-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Vicore Pharma Holding AB (publ) Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Vicore Pharma Holding AB (publ) based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5051.146
Ma 20Greater thanMa 5016.359
Ma 50Greater thanMa 10015.387
Ma 100Greater thanMa 20014.834
OpenGreater thanClose16.060
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Vicore Pharma Holding AB (publ) with someone you think should read this too:
  • Are you bullish or bearish on Vicore Pharma Holding AB (publ)? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Vicore Pharma Holding AB (publ)? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Vicore Pharma Holding AB (publ)

I send you an email if I find something interesting about Vicore Pharma Holding AB (publ).


Comments

How you think about this?

Leave a comment

Stay informed about Vicore Pharma Holding AB (publ).

Receive notifications about Vicore Pharma Holding AB (publ) in your mailbox!